Ianalumab

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Novartis presents over 65 abstracts at ASH and SABCS, highlighting new data on Scemblix, Kisqali, and other treatments, emphasizing commitment to cancer and blood disorder patients. The company also showcases personal breast cancer stories at SABCS, aiming to uplift and unite the community.

Novartis to present over 65 abstracts at ASH and SABCS, including 96-week Scemblix results and 4-year Kisqali analysis. The presentations highlight advancements in hematologic diseases and cancers, emphasizing earlier disease stages and new treatment options.

Novartis to present over 65 abstracts at ASH and SABCS, including 96-week Scemblix Phase III ASC4FIRST results and Kisqali 4-year NATALEE trial analysis. The presentations highlight advancements in hematologic diseases and cancers, emphasizing earlier disease stages and new treatment options.

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024, covering foundational research, clinical trials, and equity in lupus trials, highlighting advancements from bench to bedside.

GSK’s Benlysta and Aurinia’s Lupkynis have advanced lupus nephritis treatment, but unmet needs persist. Roche’s Gazyva (obinutuzumab) showed potential in Phase III REGENCY trial, addressing key challenges like proteinuria and steroid dependence. Gazyva could become the second biologic for LN, challenging Benlysta’s market dominance. Lupkynis remains a niche option for high proteinuria, but Gazyva’s trial success may shift this dynamic. Future competition from AZ’s Saphnelo and Novartis’ ianalumab is expected post-2025.

GSK’s Benlysta and Aurinia’s Lupkynis have advanced lupus nephritis treatment, but unmet needs remain. Roche’s Gazyva (obinutuzumab) showed significant complete renal response in Phase III REGENCY trial, potentially addressing key challenges like proteinuria and steroid dependence. If approved, Gazyva could rival Benlysta and Lupkynis, with market impact expected before competition from AZ’s Saphnelo and Novartis’ ianalumab.

UCB and Biogen report positive Phase III PHOENYCS GO trial results for dapirolizumab pegol in moderate-to-severe SLE, with a second Phase 3 trial, PHOENYCS FLY, planned for 2024. The SLE market is expected to grow from USD 3.2 billion in 2023, driven by emerging therapies like Litifilimab, Ianalumab, and Cenerimod.